A health worker shows a dose of the Chinese Sinopharm Covid-19 vaccine at a vaccination center in the Jordanian capital Amman on January 13, 2021.
Khalil Mazraawi | AFP | Getty Images
BEIJING – Sinopharm, a state giant in the development of the Chinese coronavirus vaccine, announced on Tuesday that its chairman has left the board.
The company cited personal reasons for Li Zhiming’s resignation, according to an filing for the Hong Kong-listed company. Li Hui, a director and member of the audit committee of Sinopharm subsidiary China National Medicines Corp., also resigned Tuesday for personal reasons, a separate filing reports.
In late December, Chinese authorities approved a vaccine developed by a Beijing-based subsidiary of Sinopharm for general launch. The company said the vaccine had an efficacy of 79.34% after a phase three test, according to state media.
Earlier in December, the United Arab Emirates said the vaccine was 86% effective.
There was no direct indication that the discharge was due to vaccination-related work. The company did not immediately respond to CNBC’s request for comment.
Different countries have released different results on the effectiveness of a coronavirus vaccine from another Chinese company, Sinovac.
A WHO team is working with producers of Covid-19 vaccines from the Chinese pharmaceutical companies Sinovac and Sinopharm “to assess compliance with international quality manufacturing practices before the WHO potentially drafts an emergency list,” said Director General Tedros Adhanom Ghebreyesus. the WHO earlier this week. .